Imperial College London
Professor Mark Bower

ProfessorMarkBower

Faculty of Medicine, Faculty of Medicine Centre

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3315 8052m.bower

 
 
//

Location

 

Kobler Day CareChelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cortellini:2022:10.1136/jitc-2022-005732,
author = {Cortellini, A and Pinato, D},
doi = {10.1136/jitc-2022-005732},
journal = {Journal for ImmunoTherapy of Cancer},
pages = {1--10},
title = {Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries},
url = {http://dx.doi.org/10.1136/jitc-2022-005732},
volume = {11},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: As management and prevention strategies against Coronavirus Disease-19 (COVID-19) evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. Methods: In a joint analysis of ICI recipients from OnCovid (NCT04393974) and ESMO CoCARE registries, we assessed severity and mortality from SARS-CoV-2 in vaccinated and unvaccinated patients with cancer and explored whether prior immune-related adverse events (irAEs) influenced outcome from COVID-19.Findings: The study population consisted of 240 patients diagnosed with COVID-19 between January 2020 and February 2022 exposed to ICI within 3 months prior to COVID-19 diagnosis, with a 30-day case fatality rate (CFR30) of 23.6% (95%CI: 17.8-30.7%). Overall, 42 (17.5%) were fully vaccinated prior to COVID-19 and experienced decreased CFR30 (4.8% vs 28.1%, p=0.0009), hospitalization rate (27.5% vs 63.2%, p<0.0001), requirement of oxygen therapy (15.8% vs 41.5%, p=0.0030), COVID-19complication rate (11.9% vs 34.6%, p=0.0040), and COVID-19-specific therapy (26.3% vs 57.9%, p=0.0004) compared with unvaccinated patients. Inverse Probability of Treatment Weighting (IPTW)-fitted multivariable analysis, following a clustered-robust correction for the data source (OnCovid vs ESMO CoCARE), confirmed that vaccinated patients experienced a decreased risk of death at 30 days (adjusted oddsratio-aOR 0.08, 95%CI: 0.01-0.69).Overall, 38 patients (15.8%) experienced at least 1 irAE of any grade at any time prior to COVID-19, at a median time of 3.2 months (range: 0.13-48.7) from COVID-19 diagnosis. IrAEs occurred independently of baseline characteristics except for primary tumour (p=0.0373) and were associated with a significantly decreased CFR30 (10.8% vs 26.0%, p=0.0462) additionally confirmed by the IPTW-fitted multivariable analysis(aOR: 0.47, 95%CI: 0.33-0.67). Patients who experienced irAEs also presented a higher median absolute lymphocyte co
AU  - Cortellini,A
AU  - Pinato,D
DO  - 10.1136/jitc-2022-005732
EP  - 10
PY  - 2022///
SN  - 2051-1426
SP  - 1
TI  - Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries
T2  - Journal for ImmunoTherapy of Cancer
UR  - http://dx.doi.org/10.1136/jitc-2022-005732
UR  - https://jitc.bmj.com/content/10/11/e005732
UR  - http://hdl.handle.net/10044/1/100190
VL  - 11
ER  -
Download